Compare Delta Air Lines, Inc. (DAL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Pfizer Inc — how do they compare? Delta Air Lines, Inc. trades at $83.23 (market cap $54.56B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2.9× Delta Air Lines, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Pfizer Inc for 158 Days on average.
| DAL | PFE | |
|---|---|---|
Market Cap | $54.56B | $159.59B |
Volume | 6,532,736 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $93.66 | $29.02 |
52-Week Low | $55.65 | $23.67 |
Typical Hold Time | 97 Days | 158 Days |
Enterprise Value | $69.88B | $211.09B |
Dividend Yield | 1.04% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $63.36 billion in 2025, while profitability metrics remain solid with a 5.78% net income margin and 20.12% ROE. Analyst sentiment remains overwhelmingly positive with 82% buy ratings and a $103.36 consensus price target representing 25% upside potential.
DAL presents a compelling investment case with attractive valuation multiples (P/E of 13.76, P/S of 0.8) and strong cash flow generation, though near-term headwinds include fuel cost volatility and competitive pressures. The stock's technical weakness contrasts with fundamental strength, creating potential opportunity for patient investors. Key risks include oil price sensitivity and execution challenges in maintaining premium customer loyalty against aggressive competitor tactics.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
